These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22948052)

  • 1. Herpes zoster vaccine awareness among people ≥ 50 years of age and its implications on immunization.
    Javed S; Javed F; Mays RM; Tyring SK
    Dermatol Online J; 2012 Aug; 18(8):2. PubMed ID: 22948052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing herpes zoster through vaccination.
    Gelb LD
    Ophthalmology; 2008 Feb; 115(2 Suppl):S35-8. PubMed ID: 18243932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
    Betts RF
    J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.
    Lu PJ; Euler GL; Jumaan AO; Harpaz R
    Vaccine; 2009 Feb; 27(6):882-7. PubMed ID: 19071175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
    Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
    Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination to prevent herpes zoster in older adults.
    Gnann JW
    J Pain; 2008 Jan; 9(1 Suppl 1):S31-6. PubMed ID: 18166463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
    Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
    Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.
    Doan HQ; Ung B; Ramirez-Fort MK; Khan F; Tyring SK
    Expert Opin Biol Ther; 2013 Oct; 13(10):1467-77. PubMed ID: 23984934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why should older adults receive the shingles vaccine?
    Harkness TL
    J Gerontol Nurs; 2010 Oct; 36(10):51-5. PubMed ID: 20506935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with herpes zoster vaccination status and acceptance of vaccine recommendation in community pharmacies.
    Teeter BS; Garza KB; Stevenson TL; Williamson MA; Zeek ML; Westrick SC
    Vaccine; 2014 Sep; 32(43):5749-54. PubMed ID: 25171848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.
    Keating GM
    BioDrugs; 2016 Jun; 30(3):243-54. PubMed ID: 27189459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Herpes zoster and postherpetic neuralgia - prevention by vaccination?].
    Wutzler P
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S90-4. PubMed ID: 19353479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine.
    Hurley LP; Harpaz R; Daley MF; Crane LA; Beaty BL; Barrow J; Babbel C; Marin M; Steiner JF; Davidson A; Dickinson LM; Kempe A
    J Infect Dis; 2008 Mar; 197 Suppl 2():S216-23. PubMed ID: 18419400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
    Le P; Rothberg MB
    Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public awareness and knowledge of herpes zoster: results of a global survey.
    Paek E; Johnson R
    Gerontology; 2010; 56(1):20-31. PubMed ID: 19776543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.